EOSE

Eos is a pre-profitability zinc-battery (Znyth/Z3) story that just delivered a spectacular top-line: FY2025 revenue of $114M, up 631.8% off a $15.6M base, validating early commercial traction for its non-lithium, US-made BESS. But the income statement is the problem, not the narrative. Gross profit was -$144M, a -125.9% gross margin — Eos is selling its systems for less than they cost to build, so each incremental dollar of revenue currently deepens the loss. Operating loss was -$259M and the reported net loss was -$970M (the gap likely reflects non-cash financing/fair-value charges tied to the Credit Agreement and SPA securities), with diluted EPS of -$6.69. Management's own MD&A frames the company around 'history of losses' and the need to 'improve our manufacturing processes to achieve sustained, long-term profitability,' and the Risk Factors concede 'limited manufacturing experience' and that the cells 'have less power density and may be considered inferior to competitors' products' — i.e., the margin inflection is a hope, not a demonstrated capability.

The balance sheet is structurally distressed. Stockholders' equity is -$2.24B against -$2.54B of accumulated deficit, total liabilities are $1.76B (including $813M long-term debt, up 158%), and the company burned -$211M in operating cash plus $53.8M of capex in FY2025. The $568M cash pile (boosted 664% by financings) covers only ~2 years of that burn before more capital is needed, and shares outstanding already grew 49.8% YoY — dilution is the funding mechanism. The DOE Loan Facility (up to $277.5M, only $90.9M drawn) is the lifeline to fund the AMAZE 8 GWh expansion, but the Risk Factors flag that failing covenants or losing access to that funding could force the company to 'seek alternative sources of capital, or risk its ability to continue operations.'